Back to today’s briefing

Story perspectives

Roche Halts Duchenne Therapy Shipments After Patient Deaths

7/24/2025

22 2

Summary

Story summary

Roche has halted shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, in several countries after three patients tragically died from acute liver failure. This move comes on the heels of Sarepta Therapeutics' similar decision in the U.S. However, Elevidys remains accessible for ambulatory patients in Brazil and Japan, offering hope amidst the concerns.

1 of 1

Story summary

Roche has halted shipments of its Duchenne muscular dystrophy gene therapy, Elevidys, in several countries after three patients tragically died from acute liver failure. This move comes on the heels of Sarepta Therapeutics' similar decision in the U.S. However, Elevidys remains accessible for ambulatory patients in Brazil and Japan, offering hope amidst the concerns.